Hearing date set on motion for preliminary injunction in ALLEGRA® (fexofenadine hcl) patent infringement case
Bridgewater, NJ
September 29, 2005
The sanofi-aventis Group announced today that the United States District Court for the District of New Jersey has set a hearing date for October 27, 2005 on the motion the company filed with Albany Molecular Research, Inc. for a preliminary injunction filed against Barr Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories, Ltd., and Amino Chemicals, Ltd. The motion requests a court order preventing the defendants from marketing unlicensed generic versions of Allegra® (fexofenadine HCl).

Sanofi-aventis and Albany Molecular Research, Inc. filed the motion on September 20, 2005.  The motion was filed after the September 6, 2005 announcement by Barr Pharmaceuticals and Teva Pharmaceuticals that the companies would be collaborating to launch a generic version of Allegra 30 mg, 60 mg and 180 mg.

Sanofi-aventis continues to believe that the generic products of Barr Pharmaceuticals and Teva Pharmaceuticals infringe its intellectual property rights, which are currently the subject of ongoing litigation with the two companies.  Sanofi-aventis will continue to vigorously defend its rights. 

 

About sanofi-aventis

The sanofi-aventis Group is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. The sanofi-aventis Group is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are statements that are not historical facts.  These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance.  Forward-looking statements are generally identified by the words “expect,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions.  Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2004.  Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Sanofi-aventis Group subsidiaries in the United States include Sanofi-Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc.

 

U.S. Contacts
Contact: Lisa Kennedy, 908-243-6361, lisa.a.kennedy@sanofi-aventis.com
             Melissa Feltmann, 908-243-7080, melissa.feltmann@sanofi-aventis.com